Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170042/S014

Covera Vascular Covered Stent

C.R. Bard, Inc. · Decision date Dec 16, 2025

FDA DECISIONP170042/S014

What did the FDA decide?

FDA records P170042/S014 as a supplement to PMA P170042, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 16, 2025.

FDA approval order statement

changes to the stent electropolishing and final stent cleaning processes
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Dec 16, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170042/S014
Regulatory pathway
PMA supplement
Product code
PFV
Decision code
OK30
Decision date
Dec 16, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment.

Product code
PFV
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170042/S014 received

    Application receipt date recorded by FDA.

  2. P170042/S014 · FDA decision

    30-Day Notice

  3. P170042/S015 · Related supplement

    Covera Vascular Covered Stent

Timeline entries are records held by MedtechLedger for P170042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170042

Product / regulatory recordCompanyPathwayDecision dateSource
C.R. Bard, Inc.PMA supplementJun 10, 2026FDA

Explore the linked device profile

Other records with product code PFV

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

C.R. Bard, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1625 W. 3rd St., Tempe, AZ, 85528

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records